PhaseBio Pharmaceuticals Probability of Future Pink Sheet Price Finishing Under 2.85E-4
| PHASQDelisted Stock | USD 0.0003 0.0001 25.00% |
PhaseBio |
PhaseBio Pharmaceuticals Target Price Odds to finish below 2.85E-4
The tendency of PhaseBio Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.0003 or more in 90 days |
| 0.0003 | 90 days | 0.0003 | about 36.71 |
Based on a normal probability distribution, the odds of PhaseBio Pharmaceuticals to drop to $ 0.0003 or more in 90 days from now is about 36.71 (This PhaseBio Pharmaceuticals probability density function shows the probability of PhaseBio Pink Sheet to fall within a particular range of prices over 90 days) . Probability of PhaseBio Pharmaceuticals price to stay between $ 0.0003 and its current price of $3.0E-4 at the end of the 90-day period is near 1 .
Assuming the 90 days horizon the pink sheet has the beta coefficient of 95.0 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, PhaseBio Pharmaceuticals will likely underperform. In addition to that PhaseBio Pharmaceuticals has an alpha of 190.7512, implying that it can generate a 190.75 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). PhaseBio Pharmaceuticals Price Density |
| Price |
Predictive Modules for PhaseBio Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as PhaseBio Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PhaseBio Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
PhaseBio Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. PhaseBio Pharmaceuticals is not an exception. The market had few large corrections towards the PhaseBio Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold PhaseBio Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of PhaseBio Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 190.75 | |
β | Beta against Dow Jones | 95.00 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.13 |
PhaseBio Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PhaseBio Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PhaseBio Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| PhaseBio Pharmaceuticals is not yet fully synchronised with the market data | |
| PhaseBio Pharmaceuticals has some characteristics of a very speculative penny stock | |
| PhaseBio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| PhaseBio Pharmaceuticals has accumulated 1.36 M in total debt. PhaseBio Pharmaceuticals has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PhaseBio Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, PhaseBio Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PhaseBio Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PhaseBio to invest in growth at high rates of return. When we think about PhaseBio Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 10.83 M. Net Loss for the year was (131.07 M) with loss before overhead, payroll, taxes, and interest of (91.28 M). | |
| PhaseBio Pharmaceuticals has accumulated about 7.8 M in cash with (47.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
PhaseBio Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PhaseBio Pink Sheet often depends not only on the future outlook of the current and potential PhaseBio Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PhaseBio Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 48.2 M |
PhaseBio Pharmaceuticals Technical Analysis
PhaseBio Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. PhaseBio Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of PhaseBio Pharmaceuticals. In general, you should focus on analyzing PhaseBio Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
PhaseBio Pharmaceuticals Predictive Forecast Models
PhaseBio Pharmaceuticals' time-series forecasting models is one of many PhaseBio Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary PhaseBio Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about PhaseBio Pharmaceuticals
Checking the ongoing alerts about PhaseBio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for PhaseBio Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| PhaseBio Pharmaceuticals is not yet fully synchronised with the market data | |
| PhaseBio Pharmaceuticals has some characteristics of a very speculative penny stock | |
| PhaseBio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| PhaseBio Pharmaceuticals has accumulated 1.36 M in total debt. PhaseBio Pharmaceuticals has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PhaseBio Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, PhaseBio Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PhaseBio Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PhaseBio to invest in growth at high rates of return. When we think about PhaseBio Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 10.83 M. Net Loss for the year was (131.07 M) with loss before overhead, payroll, taxes, and interest of (91.28 M). | |
| PhaseBio Pharmaceuticals has accumulated about 7.8 M in cash with (47.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in PhaseBio Pink Sheet
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |